News

ProteinLogic and Stellenbosch University receive $1.3 million grant

ProteinLogic and Stellenbosch University receive $1.3 million grant to develop blood test to monitor response to TB antimicrobial chemotherapy ProteinLogic, a biomarker discovery and commercialization company and Stellenbosch University, today announced that they have received a $1.35 million grant from the Bill & Melinda Gates Foundation to accelerate the development of ImmiPrint® Technology to monitor treatment responses to TB antimicrobial chemotherapy. The collaborative project was conceived and developed with the assistance of PTNG Consulting, a specialised science consultancy. PTNG Consulting will oversee the project management of this undertaking. ProteinLogic has forged a partnership with Stellenbosch University, South Africa, renowned for…

ProteinLogic Attends JP Morgan 2020

CAMBRIDGE, UK (2020-01-17) – ProteinLogic, the biomarker discovery and exploitation company, has attended the JP Morgan Health week in San Francisco. CEO Nicolas Huber, who represented the company, attended a number of industry events to promote the innovative diagnostic technology of the company. He held meetings with a number of potential commercial partners, who showed significant interest in supporting the company in bringing its leading TB asset to the market. The company is actively following up on all the opportunities attending this event has presented.

ProteinLogic featured in GenomeWeb’s 360Dx

CAMBRIDGE, UK (2019-12-23) – ProteinLogic, the biomarker discovery and exploitation company, has been featured in GenomeWeb’s 360Dx diagnostics online, one of the leading diagnostics newsletters. The article followed interviews with ProteinLogic’s CEO, Dr Nicolas Huber, and a clinical collaborator of the company representing ProteinLogic’s study consortium, Dr Marcelo Cordeiro-Santos, as well as other experts in the field of TB diagnosis. The results stated in the article refer to ProteinLogic’s extensive clinical validation of its novel, blood-based, host immune response diagnostic for the ruling-out of Active TB disease in cohorts of varied genetic background, also from patients co-infected with HIV. The article further discusses the…

ProteinLogic to present at BioSeed2020

CAMBRIDGE, UK (2019-12-17) – ProteinLogic, the biomarker discovery and exploitation company, has been selected by UKRI to present at the prestigious BioSeed event. BioSeed is an early-stage life-sciences investment event, which provides a platform for only 60 innovative early-stage Life Sciences companies to present to over 100 specialist investors. The pitching session is followed by extensive one-to-one partnering as well as networking opportunities. Dr Nicolas Huber, CEO of ProteinLogic, commented: “The innovative work we have done at ProteinLogic, and its potential social impact, continuous to be recognised, both in the UK and abroad. We are particularly pleased of the continued support…

proteinlogic-selected to represent the UK in mission to China

CAMBRIDGE, UK (2019-11-29) – ProteinLogic, the biomarker discovery and exploitation company, has been selected to represent the UK on the UKRI Global Business Innovation Programme (GBIP) in precision medicine on a mission to China. The GBIP is geared exclusively for Precision Medicine businesses working with technologies that enable early and accurate diagnosis to inform patient treatment, as well as the availability of targeted therapies. It aims to help innovative UK businesses develop relationships with partners in China, allowing them to gain a foothold in this market set for extensive growth. It is specifically meant to showcase the best of British…

ProteinLogic to present at the 50th Union World Conference, Hyderabad, India

CAMBRIDGE, UK (2019-10-21) – ProteinLogic, the biomarker discovery and exploitation company, will be presenting results of its novel ImmiPrint®-TB test at the 50th Union World Conference on Lung Health, to be held in Hyderabad, India. Our prominent clinical collaborators will be presenting their findings on the use of  ImmiPrint®-TB as an active TB disease rule-out test in high prevalence settings during the “Late-Breaker Session on TB” on Saturday the 2nd of November 2019.

ProteinLogic Attends the 71st AACC Meeting

CAMBRIDGE, UK (2019-08-06) – ProteinLogic, the biomarker discovery and exploitation company, is attending the 71st annual scientific meeting & clinical lab Expo of the American Association of Clinical Chemistry (AACC). Dr Nicolas Huber, CEO of ProteinLogic, commented: “The AACC meeting, with its exclusive focus on laboratory diagnostics, is the most prestigious meeting to be attending in the space. Our presence here creates new opportunities for ProteinLogic for strategic collaborations with established IVD manufacturers with an interest in our assets and platform technology. Further, it allows us to stay abreast of the current thinking and developments in the field of laboratory science.”

ProteinLogic Completes Multi-Site Clinical Study on TB, Reports Results Exceeding WHO Requirements

CAMBRIDGE, UK (2019-08-01) – ProteinLogic, the biomarker discovery and exploitation company, today announces the completion of its multi-site study on the use of its novel diagnostic technology, ImmiPrint®, for the ruling-out of Active Tuberculosis (TB) disease from a blood sample. Previously, the company had shown that its ImmiPrint  technology could achieve the requisite clinical accuracy in a significant internal study of approximately 1000 clinical samples on laboratory-grade immunoassay platforms. Under an EU Horizon 2020 grant (ADVANTAGE 666308), the company built on this work and commissioned clinical studies for the collection of further blood samples from subjects suspected of Active TB disease.…

ProteinLogic Appoints Dr Adrian Woolfson as Non-Executive Director

CAMBRIDGE, UK (2019-06-01) – ProteinLogic, the biomarker discovery and exploitation company, has appointed Dr Adrian Woolfson as Non-Executive Director. Dr Woolfson is the founder of ProteinLogic, having discovered soluble Cluster of Differentiation antigens that underpin ProteinLogic’s platform technology. He is currently serving as Executive Vice President of Research & Development, Sangamo Inc., CA, USA. Dr. Woolfson has over a decade of biopharmaceutical industry experience in drug discovery, medical affairs and early and late stage clinical development. Previously, he served as Chief Medical Officer at Nouscom AG, a genetic cancer vaccine biotechnology company based in Basel, Switzerland, where he led the…

ProteinLogic has patent granted in USA and EU, files 2nd patent

ProteinLogic (PL), the biomarker discovery and exploitation company, has received approval for granting of its first patent in biomarkers for the diagnosis of Tuberculosis in the USA and the EU. At the same time, the company has filed a 2nd patent in the same space. This new patent allows the company to expand the applicability of its unique biomarker signatures in the diagnosis of Tuberculosis (TB), while introducing further unique combinations of biomarkers that can provide accurate information for the diagnosis of the disease. This patent was critically informed by the results generated from the completion of screening of large…